Post-ablation modulation after single high-dose radiation therapy improves tumor control via enhanced immunomodulation.
Radiation therapy (RT) is frequently used for local control of solid tumors using equal dose per fraction. Recently, single high-dose radiation has been used for ablation of solid tumors. In this report, we provide a novel immunological basis for radiation dose fractionation consisting of a single high-dose RT, followed by post-ablation modulation (PAM) with four daily low-dose fractions (22Gy+0.5Gyx4) to reprogram the tumor microenvironment by diminishing immune suppression, enabling infiltration of effector cells and increasing efficacy of tumor control. Palpable 3LL and 4T1 tumors in C57Bl/6 and Balb/c mice were irradiated with the SARRP irradiator and tumor growth and survival were monitored. Immunomodulation of tumor and immune cells in vitro, and in vivo characterization of tumor-infiltrating immune effector cells were performed by FACS. For systemic application of PAM-RT, whole lung irradiation was administered in 4T1-bearing Balb/c mice. We report significant tumor growth delays and increased survival in 3LL tumor bearing mice with PAM. Primary tumor PAM-RT increased infiltration of immune effector cells and decreased Treg in irradiated tumors and secondary lymphoid organs. In a model of murine metastatic breast cancer (4T1), we demonstrate that systemic PAM-RT to the whole lung, 12 days after primary tumor ablative RT increased survival with suppression of pulmonary metastases. We provide a novel immunological basis for radiation dose fractionation consisting of a single high-dose of RT followed by daily low-dose PAM-RT fractionation to improve the immunogenic potential of ablative RT.